Genetics and family history play a large role in a person?s risk for heart disease, but factors in diet, lifestyle and the environment are also thought to influence susceptibility to the disease.
The Parkinson?s Institute will participate in a large-scale national clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson’s disease (PD). While creatine is not an approved therapy for PD or any other condition, it is widely thought to improve exercise performance.
Use of nitric oxide in patients with acute lung injury does not improve survival and may cause harm, warn researchers in a study published online today.
Shire plc today announced the availability of LIALDATM (mesalamine) with MMXTM Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The US Food and Drug Administration approved LIALDA on Jan. 16, 2007.
A drug used to strengthen bone has been found to help reduce the high incidence of hip fractures among people with Parkinson disease, according to a study published in the March 20, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.
The antidepressant duloxetine, at a once-daily dose of 60 mg, significantly reduced non-specific pain and emotional symptoms associated with depression in a new, eight-week, placebo-controlled study of 327 adult patients with at least moderate pain and major depression. The results were presented today at the 15th European Congress of Psychiatry (AEP) in Madrid, Spain.
AstraZeneca announced clinical trial data for SEROQUEL? sustained release formulation (quetiapine fumarate sustained release), at the European Congress of Psychiatry (ECP) in Madrid.
The U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.
A clinical trial conducted by researchers at the Johns Hopkins Bloomberg School of Public concluded that daily zinc supplements reduced the risk of death among children aged 12 to 48 months by 18 percent. However, the researchers did not find any significant reduction in mortality among children 1 to 11 months of age.
A small clinical trial of a medication to treat kleptomania has failed to find any conclusive benefit for patients with the impulsive stealing disorder, according to researchers at the Stanford University School of Medicine